Exposure of tumour cells to oxaliplatin results in the release of high mobility group box 1 (HMGB1) protein, that activates DCs in a toll-like receptor-4 (TLR4)-dependent manner (Apetoh et al, 2007). Here, TLR4 is linked to neoplasm.